What did I learn at a biotech conference covering AI, commercial strategy, and business development?
open••rev. 0•biotech•
#biotech#pharma#startups
Session 1: AI × Biotech — Generative AI in Hit Discovery & Drug Development
- COVID set a precedent for bypassing animal testing phases — it's now also possible to go straight to Phase 3 if you have efficacy data, by leveraging existing toxicity data from other companies
- The new model for AI partnerships won't just be about model access — it's about data access: licensing co-scientist models that generate both proprietary data and models
- The sales force isn't going away with AI, but it's evolving — possibly toward a single point-of-contact model as patients interact with the system differently
Open questions
- What does Isomorphic Labs do specifically?
- What is Noadic?
- What is the main bottleneck for AI agent implementation in this space?
- Will regulation keep up with AI innovation here?
Session 2: Commercial Strategy — The Art of Differentiation: Competing Beyond the Molecule
- Differentiation is in execution speed — the molecules themselves are often not that different in efficacy or safety
- First-in-class vs. best-in-class is a core strategic framing for positioning any therapy
- The label is the most important thing — it defines what you're legally allowed to promote
- Veer vs. Gilead case study: Gilead had a massive head start in HIV, but Veer built their identity around genuinely caring about patients — that was the differentiator
- Incorporating patient insight into clinical trial design is an emerging differentiator (multiple panelists echoed this)
- The real reason companies fail isn't clinical trial speed — it's pricing. Patients can't pay.
- The "no front door" problem: the healthcare system wants drugs, but at a specific price point and for a specific indication — no unified entry point exists
- Longevity is an overcrowded label right now — one speaker's clean framing: either your body gives out or your mind gives out, so they focus squarely on neurodegenerative disorders
- For smaller biotechs: get the word out early, social media matters more than you'd think
Open questions
- What does pharmacoeconomics mean in practice?
- How do you forecast for a new country or new product with no prior data — what is scenario forecasting?
- In the Bluebird Bio example: what are the elements that make a drug more or less expensive?
- What is the general commercial planning cycle across quarters?
- How do you weight patient trust vs. physician trust?
Session 3: Business Development — From Collaboration to Acquisition
- BD is heavily a people-skills game — being genuine matters more than being polished
- Always structure a deal through the lens of the other party
- EU regulatory path: you can pursue the full EU or a single country — single-country submission is generally the preferred starting path
- The hardest thing isn't having big ideas — it's following through all the way